TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

261 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

150 studies on the map

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Uni of Alabama at Birmingham, BirminghamATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders — Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital, PhoenixThis Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment — Cahaba Dermatology & Skin Health Center- Site Number : 8400006, BirminghamA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — AllerVie Clinical Research, BirminghamComparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease — Children's of Alabama (MRD-HCT), BirminghamReal-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults — Galderma Investigational Site - 8893, BirminghamA Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute, PhoenixA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis — Investigational Site, Fountain ValleyA Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health - Chandler, ChandlerA Long-term Follow-up Study in Patients Who Received BEAM-101 — University of Alabama at Birmingham, BirminghamThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamA Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health, ChandlerPlatform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis — Novartis Investigative Site, BirminghamA Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis — Allervie Clinical Research, BirminghamA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) — University Of Alabama, BirminghamStudy of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis — Enveda Investigative Site, BirminghamA Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — Arizona Liver Health, ChandlerA Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis — Atd002 52021, OceansideA Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Inmagene Site 1, LancasterStudy to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH — University of California San Diego, La JollaPeer Support for Adolescents and Emerging Adults With Sickle Cell Pain — University of South Alabama Medical Center, MobileA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamA Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH — GSK Investigational Site, ChandlerSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis — Univ. of California, San Francisco Health Care, OaklandA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH — GSK Investigational Site, ArcadiaA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH — GSK Investigational Site, ArcadiaRecruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease — University of Alabama, Birmingham (UAB), BirminghamA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH — Akero Clinical Study Site, BirminghamA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — Cahaba Dermatology & Skin Health Center /ID# 263855, BirminghamA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamAchieving Understanding of the Natural History of Sickle Cell Trait (AUNT) — University of Alabama, BirminghamA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) — 89bio Clinical Study Site, BirminghamLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH — 89bio Clinical Study Site, BirminghamRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamA Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema — Cahaba Dermatology & Skin Health Center, BirminghamA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis — Sitryx Clinical Site, Arkansas CityTargeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) — University of California, San Diego: Dermatology Clinical Trials Unit, San DiegoNon-Invasive Quantification of Liver Health in NASH (N-QUAN) — Arizona Liver Health, ChandlerA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — The Institute for Liver Health II DBA Arizona Clinical Trials, PeoriaA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis — Akero Clinical Study Site, BirminghamMinimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease — Children's National Health System, Washington D.C.Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — UAMS Medical Center, Little RockFibrosis Lessens After Metabolic Surgery — Banner Health Center, PhoenixStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaSickle Cell Clinical Research and Intervention Program — Children's Hospital of Illinois at OSF-Saint Francis Medical Center, PeoriaGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesCooperative Assessment of Late Effects for SCD Curative Therapies — Children's National Medical Center, Washington D.C.Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease — University of California Los Angeles, Los AngelesA Socio-ecological Approach for Improving Self-management in Adolescents With SCD — Nemours Children's Health, WilmingtonRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraDelivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease — University of Illinois at Chicago, ChicagoReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenEvaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares — U.S. Dermatology Partners, PhoenixA Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Hamilton Research, LLC, AlpharettaEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease — New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New YorkEvaluation of Non-Invasive Tests for Metabolic Liver Disease — Clinical Pharmacology of Miami, MiamiVertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis — University of San Fransisco, San FranciscoIntegrative Training Program for Pediatric Sickle Cell Pain — Connecticut Children's Medical Center, HartfordA Study of Efimosfermin Alfa in Adults With Hepatic Impairment — GSK Investigational Site, RialtoApplying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness — Lurie Children's Hospital, ChicagoSCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Anaheim Clinical Trials, LLC, AnaheimEvaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis — First OC Dermatology, Fountain ValleyA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) — First OC Dermatology, IrvineA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema — Northridge Clinical Trials, NorthridgeA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomA Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis — Arkansas Research Trials, North Little RockSafety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Red River Research Partners, FargoEffect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial — Brigham and Women's Hospital, BostonPredicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis — Mayo Clinic in Rochester, RochesterEndoscopic Ultrasound Shear Wave Elastography Study — Brigham and Women's Hospital, BostonAndrogens and NAFLD Longitudinal Cohort Study — University of California San Francisco, San FranciscoClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaMULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease — UH Seidman Cancer Center Adult SCD Clinic or UH Rainbow Babies and Children's Hospital Sickle Cell Anemia Center, ClevelandA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab — Physioseq, LLC /ID# 267266, SacramentoStudy of the Role of Genetic Modifiers in Hemoglobinopathies — Boston Children's Hospital, BostonEffect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia — Magee Women's Hospital, PittsburghA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) — Arizona Liver Health, ChandlerVerifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease — Cincinnati Children's Hospital Medical Center, CincinnatiEndoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease — Brigham and Women's Hospital, BostonQuantifying Hepatic Mitochondrial Fluxes in Humans — Texas Diabetes Institute - University Health System, San AntonioDigoxin In NASH (CODIN) — Yale New Haven Health, New HavenReversal of Lipid-Induced Insulin Resistance — Magnetic Resonance Research Center (MRRC), New HavenSickle Cell Kidney Biorepository — Parkland Memorial Hospital, DallasArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxEffect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease — Methodist Comprehensive Sickle Cell Center, MemphisSodium in the Skin and Atopic Dermatitis — San Francisco VA Medical Center, San FranciscoThe Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — University of Pittsburgh Medical Center, PittsburghBlood Collection Biorepository for Liver Disease Research — University at Buffalo, Buffalo General Medical Center, BuffaloIntermittent Fasting for NAFLD in Adults — Massachusetts General Hospital, BostonHuman Models of Selective Insulin Resistance: Alpelisib, Part I — Columbia University Irving Medical Center, New YorkEffect of Insulin Lowering on Lipogenesis — Columbia University Irving Medical Center, New YorkEarly Tracking of Childhood Health Determinants (ETCHED) Study — NIDDK, Phoenix, PhoenixHarnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM) — University of Missouri School of Medicine, ColumbiaHarnessing Macrophage Lysosomal Lipid Metabolism in Obesity — University of Missouri School of Medicine, ColumbiaRoutine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD) — University of Missouri-Columbia, ColumbiaPathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) — Yale New Haven Hospital, New HavenLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance — Stanford University, StanfordInvestigating the Link Between Type 2 Immunity and NAFLD in Human Obesity — Mayo Clinic in Arizona, ScottsdaleTime-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer — University of California San Diego, La JollaEffect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) — Univeristy of Colorado Anschutz Medical Campus, AuroraLow-Dose Pioglitazone in Patients With NASH (AIM 2) — University of Florida, GainesvilleNAFLD Clinical Care Pathway — Michael E. DeBakey VA Medical Center, Houston, TX, HoustonImpact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD) — Cincinnati Children's Hospital Medical Center, CincinnatiEvaluating the Pharmacokinetics and Safety of Miricorilant — Site# 433, San AntonioEvaluation of Miricorilant on Liver Fat in Patients With MASLD — University of Missouri, ColumbiaThermoacoustic Method for Estimating Liver Fat Fraction — ENDRA Life Sciences, Ann ArborRezdiffra Pregnancy and Lactation Registry — Madrigal Pharmaceuticals, West ConshohockenDiet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease — Weill Cornell Medicine, New YorkEffects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease — Henry Ford Health System, DetroitBicalutamide Therapy in Young Women With NAFLD and PCOS — University of California San Francisco, San FranciscoMechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease — Ann & Robert H Lurie Children's Hospital of Chicago, ChicagoInAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer — Dana Farber Cancer Institute, BostonEstrogen Administration for the Treatment of NASH in Postmenopausal Women — Massachusetts General Hospital, BostonThe Olmsted NAFLD Epidemiology Study (TONES) — Mayo Clinic in Rochester, RochesterThyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans — Harry S. Truman Memorial, Columbia, MO, ColumbiaDevelopment of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis — University of Washington, SeattleAdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL) — AdventHealth Translational Research Institute, OrlandoMilk Thistle Clinical Trial in Pediatric NAFLD — University Hospitals Cleveland Medical Center, ClevelandAccurate Point of Care Liver Disease Diagnostics (Phase 2) — University of California San Diego, La JollaRandomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant — Virginia Commonwealth University, RichmondNon-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) — National Institutes of Health Clinical Center, BethesdaNASH AMPK Exercise Dosing (AMPED) Trial — Penn State Hershey Medical Center, HersheyA Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up — National Institutes of Health Clinical Center, BethesdaStudy to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaSickle Cell Improvement: Enhancing Care in the Emergency Department — Children's Wisconsin, MilwaukeePeripheral Arterial Tonometry and Neurocognition in Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisHydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation — Cincinnati Children's Hospital Medical Center, CincinnatiSub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults — Harbor UCLA Medical Center, TorranceSickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders — St. Jude Children's Research Hospital, MemphisVirtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises — University of Maryland Medical Systems, BaltimoreSickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody — Children's National Hospital, Washington D.C.Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX) — St. Jude Children's Research Hospital, MemphisDetermination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling — National Institutes of Health Clinical Center, BethesdaLet's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy — Washington University School of Medicine, St LouisMindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease — University of Illinois Chicago, ChicagoCognitive Remediation Intervention to Prepare for Transition of Care — University of Alabama at Birmingham, BirminghamFLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases — xCures, Los Altos

Showing the 150 nearest — narrow your filters for fewer, closer studies.